Retrospective Single Center Study of Granulocyte Monocyte Adsorption Apheresis Treatment in Inflammatory Bowel Disease

Ther Apher Dial. 2016 Feb;20(1):79-85. doi: 10.1111/1744-9987.12336. Epub 2016 Feb 2.


Patients with active inflammatory bowel disease (IBD) have elevated and activated myeloid leukocytes, which infiltrate the intestinal mucosa. A significant proportion of IBD patients do not respond adequately to conventional treatment regimes. Studies have suggested that treatment with granulocyte monocyte apheresis (GMA) could be a safe and efficacious alternative for these patients. We evaluated the efficacy and safety of granulocyte/monocyte apheresis in patients with IBD in a retrospective cohort study, conducted from a single center in Stockholm. Clinical details from consecutive apheresis treated patients were retrospectively reviewed from 2004 to 2012. A total of 37 patients were included, 23 patients with ulcerative colitis (UC) and 14 with Crohn's disease (CD). Clinical response was seen in 11 patients (30%) and complete remission in 11 patients (30%). The remission rate was higher in UC patients compared to CD patients, 39% (N = 9) and 14% (N = 2) respectively. A total of 9 patients experienced adverse events. Most frequently reported was headache (N = 4). GMA seems to be a valuable adjuvant treatment regime in the care of patients with refractory IBD.

Keywords: Crohn's disease; Granulocyte monocyte adsoption apheresis; Inflammatory bowel disease; Ulcerative colitis.

MeSH terms

  • Adult
  • Blood Component Removal* / adverse effects
  • Blood Component Removal* / methods
  • Colitis, Ulcerative* / blood
  • Colitis, Ulcerative* / diagnosis
  • Colitis, Ulcerative* / therapy
  • Crohn Disease* / blood
  • Crohn Disease* / diagnosis
  • Crohn Disease* / therapy
  • Female
  • Granulocytes*
  • Humans
  • Leukapheresis / methods*
  • Male
  • Monocytes*
  • Remission Induction / methods
  • Retrospective Studies
  • Sweden
  • Treatment Outcome